Biohaven Stock Price, News & Analysis

Biohaven has announced that its investigational drug, taldefgrobep alfa, for treating Spinal Muscular Atrophy (SMA), has received Fast Track designation from the U.S. FDA, enhancing its potential for expedited review and approval. This follows the drug's previous acquisition of Orphan Drug Designation. Taldefgrobep aims to increase muscle mass by inhibiting the activity of myostatin, a protein that limits muscle growth. A Phase 3 clinical trial, named RESILIENT, is currently underway. SMA is a rare and progressive neurodegenerative disease affecting approximately 1 in 11,000 newborns in the U.S., highlighting an urgent need for effective treatments.

Pfizer reported record revenues of $100.3 billion for full-year 2022, up 23% year-over-year, driven by operational growth of 30%. Fourth-quarter revenues reached $24.3 billion, marking 2% growth. Reported diluted EPS for 2022 was $5.47, up 42%, while adjusted diluted EPS rose 62% to $6.58. For 2023, Pfizer anticipates revenues of $67.0 to $71.0 billion, primarily due to a decline in COVID-19 product sales. However, excluding these products, operational growth of 7% to 9% is expected. The company aims to invest significantly in launches and R&D to drive long-term growth, including anticipated launches of new products.

Biohaven Ltd. (NYSE: BHVN) announced that CEO Vlad Coric will present at the 41^st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 7:30 am PT in San Francisco. A slide deck of the presentation will be available on Biohaven's website. The company focuses on developing therapies for neurological and neuropsychiatric diseases, leveraging advanced drug development capabilities. Biohaven's pipeline includes candidates for conditions with limited treatment options.

Wilson Sonsini Goodrich & Rosati announces Jon Soderstrom as the new Chief Licensing Advisor (East) in its New York office. Previously managing director at Yale University's Office of Cooperative Research, Soderstrom played a significant role in developing technology transfer initiatives and raising over $1 billion for more than 45 new ventures. His expertise in technology and pharmaceuticals is expected to enhance the firm's client relationships and contributions to the entrepreneurial community on the East Coast.

Biohaven Ltd. (NYSE: BHVN) launched as a separate entity post-merger with Pfizer on October 3, 2022. The company completed a public offering of 28,750,000 shares at $10.50 each on October 25, raising approximately $301.9 million. Biohaven has a robust late-stage pipeline targeting conditions like epilepsy, OCD, and SMA, with Phase 2/3 studies planned. However, Q3 results highlighted a net loss of $68.9 million, up from $54.4 million in 2021, alongside rising R&D and G&A expenses. With a strong cash position of $257.8 million post-offering, Biohaven is focused on accelerating its development programs.

Pfizer Inc. reported its third-quarter 2022 results, with revenues of $22.6 billion, a 6% decline compared to the previous year. Excluding contributions from Paxlovid and Comirnaty, the revenue showed a 2% operational growth. Reported diluted EPS increased by 6% to $1.51, and adjusted diluted EPS rose 40% to $1.78. The company raised its 2022 revenue guidance to $99.5-$102 billion and narrowed its adjusted diluted EPS guidance to $6.40-$6.50. Pfizer's pipeline includes promising candidates with positive Phase 3 data, and it plans to launch up to 19 new products within 18 months.

Biohaven Ltd. (NYSE: BHVN) announced the closing of a public offering of 28,750,000 common shares at $10.50 each, including the underwriters' option for an additional 3,750,000 shares. The offering raised approximately $301.9 million in gross proceeds before expenses. J.P. Morgan, Cowen, SVB Securities, and Piper Sandler were the joint book-running managers for the offering. The shares were offered pursuant to effective registration statements filed with the SEC as of October 20, 2022.

Biohaven Ltd. (NYSE: BHVN) announced advancements in its MoDE extracellular target degrader platform technology, developed in collaboration with Yale University. This innovative platform aims to treat various diseases, including neurological disorders and cancer. Biohaven has filed additional patent applications, expanding its intellectual property portfolio related to the MoDE technology. The platform utilizes bifunctional synthetic molecules for the degradation of extracellular proteins, providing a novel therapeutic strategy distinct from existing methods. Biohaven aims to leverage these advancements in its drug development pipeline.

Biohaven Ltd. (NYSE: BHVN) has announced the pricing of a public offering of 25,000,000 common shares at a price of $10.50 per share. The underwriters have an option to purchase an additional 3,750,000 shares within 30 days. The offering is expected to close on October 25, 2022, pending customary closing conditions. Proceeds will be used for general corporate purposes. J.P. Morgan and other firms are managing the offering, which follows the SEC's declaration of the registration statement on October 20, 2022.